Search results
Added:
1 year ago
TCT Conference 2024 - Clinical outcomes of early intervention in patients with asymptomatic aortic stenosis (AS) did not impact the composite primary outcome of all cause mortality and unplanned AS related hospitalisation.Dr Marc Dweck (University of Edinburgh, Edinburgh, UK) joins us in this short interview filmed onsite at TCT Conference to discuss the findings from EVOLVED (NCT03094143;…
View more
Added:
1 year ago
ACC.24 — Investigator Dr Moritz Seiffert (University Heart and Vascular Center Hamburg, DE) joins us onsite at ACC to discuss the findings of the DEDICATE-DZHK6 Trial (NCT03112980).This randomized controlled, multi-center trial aimed to investigate whether transcatheter aortic valve implantation (TAVI) is non-inferior to surgical aortic valve replacement (SAVR) in patients with symptomatic severe…
View more
Added:
6 months ago
Explore comprehensive lifetime management strategies for aortic stenosis with Dr Samineh Sehatbakhsh, addressing the evolving landscape of treatment options for patients across all risk categories.This detailed presentation, part of the Complex Cases track, examines the critical decision-making process between TAVR and surgical aortic valve replacement in the modern era. Dr Sehatbakhsh addresses…
View more
Added:
1 year ago
ESC Congress 2024 — Transcatheter aortic valve replacement shows superiority over surgical aortic valve replacement for women with severe aortic stenosis.Host, Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Helene Eltchaninoff (University Hospital of Rouen, FR) to discuss key findings from the RHEIA trial (NCT04160130; Optimapharm).This prospective, randomised study aims to…
View more
Added:
1 week ago
Source:
Radcliffe Cardiology
An exploratory analysis of the EARLY TAVR trial has found that the benefits of early transcatheter aortic valve replacement (TAVR) for asymptomatic severe aortic stenosis (AS) are consistent, regardless of baseline left ventricular (LV) health.¹ This suggests that waiting for LV deterioration may not be the optimal strategy for timing intervention.MethodologyThis analysis used data from the EARLY…
View more
Added:
6 months ago
ESC Congress 2025 - New findings from a post-hoc analysis of TRISCEND II show that TTVR can reduce the rate of heart failure hospitalisations, particularly in the case of patients who present with massive or torrential TR - irrespective of baseline TR severity.Prof Philipp Lurz (University Mainz, DE) discusses new findings from the TRISCEND II trial, examining how baseline tricuspid regurgitation…
View more
Added:
9 months ago
ERA 2025 - Findings from a meta-analysis of chronic kidney disease outcomes in patients treated with empagliflozin suggest that people with CKD benefit from the drug irrespective of diabetes of albuminuria status.ProfWilliam Herrington (University of Oxford, Oxford, UK) joins us to discuss outcomes from an individual patient-level data meta-analysis, investigating the impact of diabetes,…
View more
Added:
9 months ago
ERA 2025 - Results from a meta-analysis of trials including EMPA-KIDNEY show the treatment effect of empagliflozin is not modified by level of predicted acute eGFR dip.Dr Natalie Staplin (University of Oxford, Oxford, UK) joins us to discuss findings from a meta-analysis of four trials, including the EMPA-KIDNEY trial (NCT03594110), investigating the impact of acute eGFR dips and markers of…
View more
ECG in Severe COVID-19 Infection
Added:
1 year ago
Short Communication
Added:
1 year ago
EuroPCR 24 - We are joined onsite by Prof Ole De Backer (Rigshospitalet, DK) to discuss the findings from the NOTION-2 Study. (NCT02825134).NOTION-2 is a randomized, multicenter trial which aimed to investigate transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in 376 patients under 75 years of age with severe aortic valve stenosis in regard to intra-…
View more